AB Šiaulių Bankas, company code 112025254, address of the head office Tilžės str. 149, Šiauliai, Lithuania. AB Šiaulių Bankas has received a notification from its executive – a member of the Supervisory Board and long-time shareholder Gintaras Kateiva – regarding transactions for the acquisition of the Bank’s shares (attached). Through these transactions, Gintaras Kateiva acquired 130,791 bank shares and currently, together with his spouse, holds a total of 33,000,000 AB Šiaulių Bankas shares (4.98% of the total number of issued shares). Additional information: Tomas Varenbergas Head of Investment Management Divisiontomas.varenbergas@sb.ltAttachmentG.Kateiva_20250321 EN

Please see below information about transactions made under the first tranche of the 2025 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO). Date on which the tranche was announced: 5 February 2025. The duration of the tranche: 6 February to no later than 2 April 2025. Further information on the tranche can be found in the stock market announcement on its commencement dated 5 February 2025, available here: https://newsweb.oslobors.no/message/637712 From 17 March to 21 March 2025, Equinor ASA has purchased a total of 2,950,000 own shares at an average price of NOK 265.4230 per share. Overview of transactions:Date Trading venue Aggregated daily volume (number of shares) Weighted average share price (NOK) Total transaction value (NOK)         17 March OSE 600,000 261.1854 156,711,240.00  CEUX        TQEX               18...

MUNICH, March 25, 2025 (GLOBE NEWSWIRE) — From April 7th to 13th, bauma 2025 is to take place in Munich, Germany. In this top industrial fair, global machinery firms will show leading technologies and innovations in the Trade Fair Center Messe München. As a globally leading equipment manufacturer, Zoomlion has exhibited at bauma for 8 years in a row. What will be its blockbusters in 2025? In the fair, Zoomlion will focus on “Greener Development, Brighter Future” and exhibit near 70 premium products for concrete machinery, mobile crane, construction hoisting machinery, earth-moving machinery, MEWPs, and industrial vehicles. Its Italian subsidiary CIFA and German subsidiary M-TEC will jointly exhibit their best-selling products. Based on AI, digital twins, and IoT, Zoomlion develops complete sets of mining machinery equipment solutions...

Technip Energies (PARIS:TE), a global technology & engineering powerhouse leading in energy and decarbonization infrastructure, today announces the publication of the convening notice for its annual general meeting, which will be held on May 6, 2025, at 2:00 p.m. CEST in Schiphol, The Netherlands. The convening notice, agenda and explanatory notes, as well as other relevant meeting documents are available at: https://investors.technipenergies.com/news-events/agm Technip Energies’ 2024 Annual Report is available at: https://investors.technipenergies.com/financial-information/results-center About Technip Energies Technip Energies is a global technology and engineering powerhouse. With leadership positions in LNG, hydrogen, ethylene, sustainable chemistry, and CO2 management, we are contributing to the development of critical markets...

Seasoned Agriculture and Biotech Executive With a Passion to Feed the World Sustainably Ghent, BELGIUM, March 25, 2025 (GLOBE NEWSWIRE) — Press release Biotalys (Euronext: BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for sustainable crop protection, is pleased to announce the proposal to appoint Toni Bucci as independent director to its Board of Directors. Ms Bucci’s appointment will become effective immediately upon election at the upcoming Biotalys shareholders’ meeting on 22 April 2025. She will succeed Markus Heldt, who will retire from the Board. Simon Moroney, Chairman of the Board at Biotalys, commented: “We are delighted to welcome Toni Bucci to our Board of Directors. Her extensive experience in agriculture and strategic leadership will be most welcome as we continue...

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosisLong-term disability and safety data from ALITHIOS open-label extension study on continuous treatment with Kesimpta vs. later switch from teriflunomide in relapsing multiple sclerosis (RMS) patients to be presentedAdditional presentations highlight the Novartis neuroscience pipeline, including remibrutinib for RMS and iptacopan for generalized myasthenia gravisBasel, March 25, 2025 – Novartis will present data from studies across its neuroscience portfolio, including seven-year disability outcomes and safety data from the ALITHIOS open-label extension trial of Kesimpta® (ofatumumab) in people with relapsing multiple sclerosis (RMS), at the American Academy of Neurology (AAN) 2025...

Ladies and Gentlemen Please find enclosed the invitation to the Ascom Annual General Meeting 2025. This will take place on Wednesday, April 16, 2025, at 2 p.m.The venue is the Theater Casino Zug, Artherstrasse 2-4, 6300 Zug. Further details on the meeting and the agenda can be found in the official invitation enclosed. Yours sincerelyAscom Holding AGAttachmentAscom_Invitation_AGM_2025